153 related articles for article (PubMed ID: 19939460)
1. Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B.
Mura P; Camalli M; Casini A; Gabbiani C; Messori L
J Inorg Biochem; 2010 Feb; 104(2):111-7. PubMed ID: 19939460
[TBL] [Abstract][Full Text] [Related]
2. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
[TBL] [Abstract][Full Text] [Related]
3. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
4. Isomeric [RuCl2(dmso)2(indazole)2] complexes: ruthenium(II)-mediated coupling reaction of acetonitrile with 1H-indazole.
Reisner E; Arion VB; Rufińska A; Chiorescu I; Schmid WF; Keppler BK
Dalton Trans; 2005 Jul; (14):2355-64. PubMed ID: 15995743
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium(II) complexes containing bis(2-(diphenylphosphino)phenyl) ether and their catalytic activity in hydrogenation reactions.
Venkateswaran R; Mague JT; Balakrishna MS
Inorg Chem; 2007 Feb; 46(3):809-17. PubMed ID: 17257024
[TBL] [Abstract][Full Text] [Related]
6. Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.
Egger A; Arion VB; Reisner E; Cebrián-Losantos B; Shova S; Trettenhahn G; Keppler BK
Inorg Chem; 2005 Jan; 44(1):122-32. PubMed ID: 15627368
[TBL] [Abstract][Full Text] [Related]
7. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity.
Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E
Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.
Gopal YN; Jayaraju D; Kondapi AK
Biochemistry; 1999 Apr; 38(14):4382-8. PubMed ID: 10194357
[TBL] [Abstract][Full Text] [Related]
9. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
10. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?
Hanif M; Henke H; Meier SM; Martic S; Labib M; Kandioller W; Jakupec MA; Arion VB; Kraatz HB; Keppler BK; Hartinger CG
Inorg Chem; 2010 Sep; 49(17):7953-63. PubMed ID: 20704358
[TBL] [Abstract][Full Text] [Related]
11. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
[TBL] [Abstract][Full Text] [Related]
12. Preliminary chemico-biological studies on Ru(III) compounds with S-methyl pyrrolidine/dimethyl dithiocarbamate.
Giovagnini L; Mancinetti E; Ronconi L; Sitran S; Marchiò L; Castagliuolo I; Brun P; Trevisan A; Fregona D
J Inorg Biochem; 2009 May; 103(5):774-82. PubMed ID: 19250682
[TBL] [Abstract][Full Text] [Related]
13. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs.
Ang WH; De Luca A; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ
ChemMedChem; 2007 Dec; 2(12):1799-806. PubMed ID: 17918761
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and reactivity of the ruthenium(II) dithiocarbonate complex [Ru(kappa2-S2C=O)(dppm)2] (dppm = bis(diphenylphosphino)methane).
Wilton-Ely JD; Solanki D; Hogarth G
Inorg Chem; 2006 Jun; 45(13):5210-4. PubMed ID: 16780346
[TBL] [Abstract][Full Text] [Related]
15. Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c.
Casini A; Gabbiani C; Mastrobuoni G; Pellicani RZ; Intini FP; Arnesano F; Natile G; Moneti G; Francese S; Messori L
Biochemistry; 2007 Oct; 46(43):12220-30. PubMed ID: 17924668
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
17. Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.
Hotze AC; van der Geer EP; Caspers SE; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
Inorg Chem; 2004 Aug; 43(16):4935-43. PubMed ID: 15285670
[TBL] [Abstract][Full Text] [Related]
18. Dichlorobis(2-phenylazopyridine)ruthenium(II) complexes: characterisation, spectroscopic and structural properties of four isomers.
Velders AH; van der Schilden K; Hotze AC; Reedijk J; Kooijman H; Spek AL
Dalton Trans; 2004 Feb; (3):448-55. PubMed ID: 15252553
[TBL] [Abstract][Full Text] [Related]
19. Rhenium inhibitors of cathepsin B (ReO(SYS)X (where Y = S, py; X = Cl, Br, SPhOMe-p)): Synthesis and mechanism of inhibition.
Mosi R; Baird IR; Cox J; Anastassov V; Cameron B; Skerlj RT; Fricker SP
J Med Chem; 2006 Aug; 49(17):5262-72. PubMed ID: 16913715
[TBL] [Abstract][Full Text] [Related]
20. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
